(Q39031748)

8 September 2017

title

Phosphorothioate-modified CpG oligodeoxynucleotide (CpG ODN) induces apoptosis of human hepatocellular carcinoma cells independent of TLR9. (English)

1 reference

8 September 2017

0 references

hepatocellular carcinoma

1 reference

Yuyi Zhang

1

1 reference

8 September 2017

Ang Lin

2

1 reference

8 September 2017

Cai Zhang

3

1 reference

8 September 2017

Zhigang Tian

4

1 reference

8 September 2017

Jian Zhang

5

1 reference

8 September 2017

publication date

23 January 2014

1 reference

Cancer Immunology, Immunotherapy

8 September 2017

published in

1 reference

8 September 2017

volume

63

1 reference

8 September 2017

issue

4

1 reference

8 September 2017

page(s)

357-367

1 reference

https://scigraph.springernature.com/pub.10.1007/s00262-014-1518-y

8 September 2017

exact match

0 references

cites work

Effect of rapamycin alone and in combination with sorafenib in an orthotopic model of human hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Growth inhibition of human hepatocellular carcinoma cells by blocking STAT3 activation with decoy-ODN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Pattern recognition receptors and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Regulation of adaptive immunity by the innate immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Microbe sensing, positive feedback loops, and the pathogenesis of inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Toll-like receptors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Toll-like receptors on tumor cells facilitate evasion of immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Toll like receptor-9 agonists stimulate prostate cancer invasion in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Endotoxin/lipopolysaccharide activates NF-kappa B and enhances tumor cell adhesion and invasion through a beta 1 integrin-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

The toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Development of TLR9 agonists for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Cancers take their Toll--the function and regulation of Toll-like receptors in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

TLR signaling by tumor and immune cells: a double-edged sword

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Phosphorothioate backbone modification modulates macrophage activation by CpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

CpG and non-CpG oligodeoxynucleotides directly costimulate mouse and human CD4+ T cells through a TLR9- and MyD88-independent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Functional expression of TLR9 is associated to the metastatic potential of human lung cancer cell: functional active role of TLR9 on tumor metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Down-regulation of TLR9 expression affects the maturation and function of murine bone marrow-derived dendritic cells induced by CpG

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Sequence and TLR9 independent increase of TRACP expression by antisense DNA and siRNA molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Neutrophil recognition of bacterial DNA and Toll-like receptor 9-dependent and -independent regulation of neutrophil function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

CpG-induced tyrosine phosphorylation occurs via a TLR9-independent mechanism and is required for cytokine secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Toll-like receptor (TLR)-3, but not TLR4, agonist protects against genital herpes infection in the absence of inflammation seen with CpG DNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

A crucial role for plasmacytoid dendritic cells in antiviral protection by CpG ODN-based vaginal microbicide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

In vitro evaluation of Lactobacillus plantarum DSMZ 12028 as a probiotic: emphasis on innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Reversal of hepatitis B virus-induced immune tolerance by an immunostimulatory 3p-HBx-siRNAs in a retinoic acid inducible gene I-dependent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

In vivo targeted gene delivery by cationic nanoparticles for treatment of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Suppression of hepatitis B virus-derived human hepatocellular carcinoma by NF-kappaB-inducing kinase-specific siRNA using liver-targeting liposomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

Pegylated immuno-lipopolyplexes: A novel non-viral gene delivery system for liver cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-014-1518-Y

10.1007/S00262-014-1518-Y

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference